These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2573682

  • 1. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
    Mitchell JB, Russo A, Cook JA, Straus KL, Glatstein E.
    Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
    [Abstract] [Full Text] [Related]

  • 2. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
    Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
    Epstein AH, Lebovics RS, Goffman T, Teague D, Fuetsch ES, Glatstein E, Okunieff P, Cook JA.
    J Natl Cancer Inst; 1994 Dec 07; 86(23):1775-80. PubMed ID: 7966416
    [Abstract] [Full Text] [Related]

  • 5. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
    Mitchell JB, Russo A, Kinsella TJ, Glatstein E.
    Int J Radiat Oncol Biol Phys; 1986 Aug 07; 12(8):1513-8. PubMed ID: 3531118
    [Abstract] [Full Text] [Related]

  • 6. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
    Lawrence TS, Davis MA, Maybaum J, Mukhopadhyay SK, Stetson PL, Normolle DP, McKeever PE, Ensminger WD.
    Cancer Res; 1992 Jul 01; 52(13):3698-704. PubMed ID: 1617642
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The clinical rationale for S-phase radiosensitization in human tumors.
    McGinn CJ, Kinsella TJ.
    Curr Probl Cancer; 1993 Jul 01; 17(5):273-321. PubMed ID: 8281809
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
    Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Steinberg SM, Cook J, Mitchell JB, Katz D, Smith R, Glatstein E.
    J Clin Oncol; 1992 Feb 01; 10(2):264-8. PubMed ID: 1310102
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
    Jackson D, Kinsella T, Rowland J, Wright D, Katz D, Main D, Collins J, Kornblith P, Glatstein E.
    Am J Clin Oncol; 1987 Oct 01; 10(5):437-43. PubMed ID: 2821790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.